Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research report sent to investors on Tuesday. The brokerage issued a sell rating on the stock.

A number of other research firms have also commented on MBRX. Roth Mkm reaffirmed a buy rating and issued a $40.00 price objective on shares of Moleculin Biotech in a research note on Friday, April 12th. Maxim Group decreased their target price on Moleculin Biotech from $45.00 to $20.00 and set a buy rating for the company in a research report on Tuesday, March 26th.

Moleculin Biotech Trading Up 1.0 %

Shares of MBRX opened at $5.09 on Tuesday. The business’s 50-day moving average price is $6.27 and its 200 day moving average price is $7.88. The stock has a market capitalization of $11.35 million, a P/E ratio of -0.37 and a beta of 1.85. Moleculin Biotech has a 1-year low of $4.28 and a 1-year high of $15.75.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Moleculin Biotech stock. Armistice Capital LLC bought a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 3,207,417 shares of the company’s stock, valued at approximately $2,753,000. Armistice Capital LLC owned 9.60% of Moleculin Biotech as of its most recent SEC filing. 15.52% of the stock is owned by hedge funds and other institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.